Details of the Drug Combinations

General Information of This Drug (ID: DM2QHZU)

• Drug Name: Sulindac (DM2QHZU)
• Synonyms: Aclin; Aflodac; Arthrobid; Arthrocine; Chibret; Clinoril; Copal; Copals; Kenalin; Klinoril; Mobilin; Sulindaco; Sulindacum; Sulindal; Alphapharm Brand of Sulindac; Apo Sulin; Apotex Brand of Sulindac; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Copal resin; Copal rosin varnish; Gum copal; KendrickBrand of Sulindac; Merck Brand of Sulindac; Novo Sundac; Novopharm Brand of Sulindac; Nu Pharm Brand of Sulindac; Nu Sulindac; Resin copal; Sulindac sulfoxide; MK 231; MK231; S 8139; Apo-Sulin; Clinoril (TN); MK-231; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindaco [INN-Spanish]; Sulindacum [INN-Latin]; Sulindac (JAN/USP/INN); Sulindac [USAN:BAN:INN:JAN]; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; Cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; Cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid

Indication

Acute myelogenous leukaemia; ICD 11: 2A41; Status: Approved [1]; Bursitis; ICD 11: N.A.; Status: Approved [1]; Osteoarthritis; ICD 11: FA00-FA05; Status: Approved [1]; Rheumatoid arthritis; ICD 11: FA20; Status: Approved [2]; Colon cancer; ICD 11: 2B90.Z; Status: Investigative [1]

• Therapeutic Class: Antiinflammatory Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Sulindac + Idarubicin	DCA8Z72	Idarubicin	Glioblastoma? (Cell Line: T98G)	[3]
Sulindac + Ruxolitinib	DC4YIKK	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[4]

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Sulindac + Erlotinib	DC4Q7LG	Erlotinib	Squamous Cell Carcinoma of the Head and Neck (SCCHN)	[5]
Sulindac + Erlotinib	DCF9DDX	Erlotinib	Adenomatous Polyposis Coli	[6]
Sulindac + Eflornithine	DCQKAQ0	Eflornithine	Precancerous Condition	[7]
Sulindac + Eflornithine	DC91WUV	Eflornithine	Familial adenomatous polyposis; Colon cancer	[8]
Sulindac + Cytarabine	DCHPCU7	Cytarabine	Acute Myeloid Leukemia	[9]

References

• [1] Sulindac FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5425).
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [5] ClinicalTrials.gov (NCT00392665) Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
• [6] ClinicalTrials.gov (NCT01187901) A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
• [7] ClinicalTrials.gov (NCT00118365) Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
• [8] FDA Drug Development and Drug Interactions
• [9] ClinicalTrials.gov (NCT01843179) Sulindac for Patients With AML